Hypomethylating agent based combinations in higher risk myelodysplastic syndrome

Namrata S. Chandhok, Russell Lewis, Thomas Prebet

Research output: Contribution to journalReview articlepeer-review


For over a decade the hypomethylating agents (HMA) azacitidine and decitabine have been the mainstay of therapy for myelodysplastic syndrome (MDS). There is a critical need to improve frontline therapy, given that only up to half of high-risk MDS patients will respond to HMA therapy, and responses are short-lived. Currently, a key strategy has been to combine HMAs with other novel agents to improve patient outcomes. While synergy of agents is the goal of combination therapy, combinations often come at the cost of increased side effects that are often intolerable in this vulnerable population. The purpose of this review is to critically examine clinically relevant HMA combinations and discuss the future of MDS management.

Original languageEnglish (US)
Pages (from-to)1012-1027
Number of pages16
JournalLeukemia and Lymphoma
Issue number5
StatePublished - Apr 15 2020


  • clinical trials
  • combination therapy
  • disease management
  • hypomethylating agents
  • Myelodysplastic syndrome
  • novel agents

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Hypomethylating agent based combinations in higher risk myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this